Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 - A Comprehensive Analysis.
COVID-19
SARS-CoV-2
antibody response
avidity
memory B cells
neutralization
plasmablasts
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
31
03
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
To comprehensively evaluate SARS-CoV-2 specific B-cell and antibody responses up to one year after mild COVID-19. In 31 mildly symptomatic COVID-19 participants SARS-CoV-2-specific plasmablasts and antigen-specific memory B cells were measured by ELISpot. Binding antibodies directed against the proteins spike (S), domain S1, and nucleocapsid (N) were estimated using rIFA, ELISA, and commercially available assays, and avidity measured using thiocyanate washout. Neutralizing antibodies against variants of concern were measured using a surrogate-neutralization test. Plasmablast responses were assessed in all participants who gave sequential samples during the first two weeks after infection; they preceded the rise in antibodies and correlated with antibody titers measured at one month. S1 and N protein-specific IgG memory B-cell responses remained stable during the first year, whereas S1-specific IgA memory B-cell responses declined after 6 months. Antibody titers waned over time, whilst potent affinity maturation was observed for anti-RBD antibodies. Neutralizing antibodies against wild-type (WT) and variants decayed during the first 6 months but titers significantly increased for Alpha, Gamma and Delta between 6 months and one year. Therefore, near-similar titers were observed for WT and Alpha after one year, and only slightly lower antibody levels for the Delta variant compared to WT. Anti-RBD antibody responses correlated with the neutralizing antibody titers at all time points, however the predicted titers were 3-fold lower at one year compared to one month. In mild COVID-19, stable levels of SARS-CoV-2 specific memory B cells and antibodies neutralizing current variants of concern are observed up to one year post infection. Care should be taken when predicting neutralizing titers using commercial assays that measure binding antibodies.
Identifiants
pubmed: 35585978
doi: 10.3389/fimmu.2022.841009
pmc: PMC9108245
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
841009Informations de copyright
Copyright © 2022 Meyer, Martinez-Murillo, Lemaitre, Blanchard-Rohner, Didierlaurent, Fontannaz, Eugercios Manzanas, Lambert, Loevy, Kaiser, Sartoretti, Tougne, Villard, Huttner, Siegrist and Eberhardt.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Clin Microbiol Infect. 2021 Nov;27(11):1695.e7-1695.e12
pubmed: 34245905
N Engl J Med. 2021 Nov 18;385(21):2010-2012
pubmed: 34648703
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685
pubmed: 32152119
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
mSphere. 2020 Nov 11;5(6):
pubmed: 33177214
JAMA Neurol. 2022 Apr 01;79(4):399-404
pubmed: 35212717
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Front Med (Lausanne). 2020 Nov 11;7:592629
pubmed: 33262993
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Clin Microbiol Infect. 2021 Feb 20;:
pubmed: 33618012
Eur J Immunol. 2021 Dec;51(12):3202-3213
pubmed: 34580856
Clin Microbiol Infect. 2021 Jan 20;:
pubmed: 33482352
Science. 2021 Dec 10;374(6573):1353-1360
pubmed: 34698504
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Cell Rep. 2021 Oct 5;37(1):109773
pubmed: 34587479
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Nat Commun. 2021 Aug 17;12(1):4984
pubmed: 34404803
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Clin Transl Immunology. 2021 Jul 05;10(7):e1306
pubmed: 34257967
Nature. 2021 Jul;595(7867):421-425
pubmed: 34030176
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228